2015
DOI: 10.1111/nmo.12703
|View full text |Cite
|
Sign up to set email alerts
|

Immunomodulatory effect of ghrelin in the intestinal mucosa

Abstract: The gastrointestinal tract is the largest endocrine organ in the body and it produces a wide array of hormones and neuropeptides. Ghrelin, a 28-amino acid hormone produced mainly by the X/A-like endocrine cells in the gastric mucosa, has widespread tissue distribution and diverse physiological functions such as hormonal, orexigenic, metabolic, cardiovascular, neurological and immunological activities. Recent research has implicated ghrelin in gastrointestinal pathological conditions and immune system regulatio… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
24
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 37 publications
(28 citation statements)
references
References 50 publications
1
24
0
Order By: Relevance
“…There are some early studies showing that ghrelin increases proliferation and invasiveness of pancreatic adenocarcinoma [ 47 ], hepatoma [ 48 ], and adrenocortical tumor cells [ 49 ]. On the other hand, numerous recent clinical and experimental studies [ 8 , 50 , 51 ], including our present data, indicate that ghrelin exhibits anti-inflammatory effect and plays a role in protecting against cancer-related inflammation [ 52 ] and inflammation-associated carcinogenesis [ 53 ]. For this reason, clinical observations also indicate that low levels of ghrelin are associated with an increased risk of esophageal, gastric, and esophagogastric junctional adenocarcinoma [ 54 , 55 ].…”
Section: Discussionsupporting
confidence: 54%
“…There are some early studies showing that ghrelin increases proliferation and invasiveness of pancreatic adenocarcinoma [ 47 ], hepatoma [ 48 ], and adrenocortical tumor cells [ 49 ]. On the other hand, numerous recent clinical and experimental studies [ 8 , 50 , 51 ], including our present data, indicate that ghrelin exhibits anti-inflammatory effect and plays a role in protecting against cancer-related inflammation [ 52 ] and inflammation-associated carcinogenesis [ 53 ]. For this reason, clinical observations also indicate that low levels of ghrelin are associated with an increased risk of esophageal, gastric, and esophagogastric junctional adenocarcinoma [ 54 , 55 ].…”
Section: Discussionsupporting
confidence: 54%
“…Ghrelin: The circulating levels of ghrelin are elevated in patients with IBD with active inflammation[ 266 , 267 ]. Moreover, circulating ghrelin levels in UC and CD patients are correlated with TNFα, C-reactive protein, the erythrocyte sedimentation rate, and fibrinogen, and negatively correlated with nutritional status parameters[ 42 , 228 , 268 , 269 ].…”
Section: Nes Nepa In Ibdmentioning
confidence: 99%
“…Recently, the anti‐IL‐12p40 monoclonal antibody ( Ustekinumab ™) has demonstrated good clinical efficacy in a group of UC patients resistant to anti‐TNF therapy (Sandborn et al, ) demonstrating that blocking the communication between CD11c + and T‐cells can result in a decrease in the activity of the IL‐12/23 pro‐inflammatory pathway (Fitzpatrick, ). Among various intracellular pathways that activate CD11c + cell functions, NF‐κB pathway regulates IL‐12/23 production (Kaiko et al, ; Rescigno, Martino, Sutherland, Gold, & Ricciardi‐Castagnoli, ; Tas et al, ), and in active UC, activation of NF‐κB is increased in lamina propria mononuclear cells; therefore, inhibition of the NF‐κB pathway has been proposed as a therapeutic strategy (Eissa, Hussein, Kermarrec, Elgazzar, et al, ; Eissa & Ghia, ; Eissa, Hussein, Hendy, Bernstein, & Ghia, ).…”
Section: Introductionmentioning
confidence: 99%